Two TfR1 antibodies, namely, 3TF12 and 3GH7, have been identified to exhibit abilities against tumors whose proliferation relies on high levels of TfR1 and iron uptake, such as acute lymphoid and myeloid leukemias (Crepin et al., 2010). Here, TFRC is linked to myeloid leukemia.